• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

吡啶类IRAK4抑制剂的设计、合成及生物活性评价

朱宝, 金双龙, 郭毅, 李月珍, 张奕华, 赖宜生

朱宝, 金双龙, 郭毅, 李月珍, 张奕华, 赖宜生. 吡啶类IRAK4抑制剂的设计、合成及生物活性评价[J]. 中国药科大学学报, 2017, 48(6): 670-674. DOI: 10.11665/j.issn.1000-5048.20170606
引用本文: 朱宝, 金双龙, 郭毅, 李月珍, 张奕华, 赖宜生. 吡啶类IRAK4抑制剂的设计、合成及生物活性评价[J]. 中国药科大学学报, 2017, 48(6): 670-674. DOI: 10.11665/j.issn.1000-5048.20170606
ZHU Bao, JIN Shuanglong, GUO Yi, LI Yuezhen, ZHANG Yihua, LAI Yisheng. Design, synthesis and biological evaluation of pyridine-based IRAK4 inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 670-674. DOI: 10.11665/j.issn.1000-5048.20170606
Citation: ZHU Bao, JIN Shuanglong, GUO Yi, LI Yuezhen, ZHANG Yihua, LAI Yisheng. Design, synthesis and biological evaluation of pyridine-based IRAK4 inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 670-674. DOI: 10.11665/j.issn.1000-5048.20170606

吡啶类IRAK4抑制剂的设计、合成及生物活性评价

基金项目: 国家自然科学基金资助项目(No.21472244)

Design, synthesis and biological evaluation of pyridine-based IRAK4 inhibitors

  • 摘要: 在现有IRAK4抑制剂MK-32和AU-5的基础上,利用开环策略和拼合原理,结合分子对接技术,设计并合成了12个以吡啶为基本母核的目标化合物。采用放射性同位素标记法评价了目标化合物对IRAK4激酶的抑制活性。结果表明,该类化合物对IRAK4显现出良好的抑制活性。其中5个化合物的IC50小于1 μmol/L,值得进一步研究。
    Abstract: Based on the known IRAK4 inhibitors MK-32 and AU-5, we designed and synthesized 12 pyridine-based target compounds by adopting open-ring and hybrid strategies, and combining molecular docking technology. The bioassays determined by radioisotope labeling demonstrated that the target compounds displayed good inhibitory activity against IRAK4. Among them, the IC50 value of 5 compounds was less than 1 μmol/L, suggesting that these compounds may be candidates for further investigation.
  • [1] Li S,Strelow A,Fontana EJ,et al.H.IRAK-4:a novel member of the IRAK family with the properties of an IRAK-kinase [J].Proc Natl Acad Sci,2002,99(8):5567-5572.
    [2] Takeda K,Akira S.TLR signaling pathways[J].Semin Immunol,2004,16(1):3-9.
    [3] Suzuki N,Suzuki S,Duncan GS,et al.Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK4[J].Nature, 2002,416(6882):750-756.
    [4] Ngo VN,Young RM,Schmitz R,et al.Oncogenically active MYD88 mutations in human lymphoma[J].Nature,2011,470(7332):115-119.
    [5] Yang,G,Zhou Y,Liu X,et al.A mutation in MYD88(L265P)supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia[J].Blood,2013,122(7):1222-1232.
    [6] Chaudhary D,Robinson S,Romero DL.Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4(IRAK4)as a therapeutic target for inflammation and oncology disorders[J].J Med Chem,2015,58(1):96-110.
    [7] Anastassiadis T,Deacon SW,Devarajan K,et al.Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity[J].Nat Biotechnol,2011,29(11):1039-1045.
计量
  • 文章访问数:  1114
  • HTML全文浏览量:  0
  • PDF下载量:  1569
  • 被引次数: 0
出版历程
  • 刊出日期:  2017-12-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭